What does Caribou Biosciences, Inc. do?
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell…
What is Caribou Biosciences, Inc.'s P/E and P/B ratio?
Caribou Biosciences, Inc. has a P/E ratio of -0.5 and a P/B ratio of 0.61.
What is Caribou Biosciences, Inc.'s debt-to-equity ratio?
Caribou Biosciences, Inc. has a debt-to-equity ratio of 0.27.
How much does Caribou Biosciences, Inc. owe compared with what it owns?
Caribou Biosciences, Inc. owes $0.31 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Caribou Biosciences, Inc.'s Positivity rank?
Caribou Biosciences, Inc. is ranked #1,306 of 6,774 companies globally and #274 of 4,000 in United States on PositoAI, with a Positivity Score of 22,955.
Does Caribou Biosciences, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Caribou Biosciences, Inc..
Where can I read the latest news about Caribou Biosciences, Inc.?
Recent headlines about Caribou Biosciences, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Caribou Biosciences, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Caribou Biosciences, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.